Research programme: cancer and inflammatory disorder therapeutics - Avexxin

Drug Profile

Research programme: cancer and inflammatory disorder therapeutics - Avexxin

Alternative Names: AVX 002; AVX 003; AVX 235; AVX 420; AVX 440; AVX 449

Latest Information Update: 27 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Avexxin
  • Class Small molecules
  • Mechanism of Action Immunomodulators; Phospholipase A2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Glomerulonephritis; Rheumatoid arthritis

Most Recent Events

  • 27 Apr 2016 Preclinical trials in Cancer in Norway (unspecified route) before April 2016
  • 14 Jan 2015 AVX 002 is still in preclinical development for Rheumatoid arthritis in Norway
  • 14 Jan 2015 AVX 235 is still in Preclinical in Glomerulonephritis in Norway
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top